Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
Eli Lilly is growing faster with Zepbound and Mounjaro, as the active ingredient tirzepitide offers a more effective result. Novo Nordisk also cut profits in the second quarter due to weaker ...
BofA analyst Allen Lutz reiterated an Underperform rating and $21 price target on Hims & Hers (HIMS) after Novo Nordisk (NVO) announced ...
Bernstein analysts told investors in a note Tuesday that Eli Lilly (NYSE:LLY) is gaining ground in the GLP-1 market, edging closer to market share parity with Novo Nordisk (NYSE:NVO).
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...
California dedicated $100 to manufacturing insulin for diabetic residents. That effort is taking longer than Gov. Gavin ...
Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.
Though the Healthy Skepticism ads don’t specifically call out compounded GLP-1s, Lilly said in a statement to MM+M that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback